Cargando…

Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection

There seem to currently be no therapeutic medications found for the severe coronavirus infection in 2019 (COVID-19). In light of this, it has been hypothesized that the immunomodulatory treatment known as tocilizumab can lessen the inflammatory response that occurs in the respiratory system, speed u...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabie, Al Shaimaa Ibrahim, Salah, Hager, Said, Amira S. A., Shaaban, Ahmed Hassan, Abdou, Lamya Mohamed, Khalil, Doaa Mahmoud, Kharaba, Zelal, Afifi, Hala, Sofy, Mahmoud R., Youssef, Eman M. I., Bayoumy, Eman S. M., Hussein, Raghda R. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957040/
https://www.ncbi.nlm.nih.gov/pubmed/36833140
http://dx.doi.org/10.3390/healthcare11040607
_version_ 1784894727218266112
author Rabie, Al Shaimaa Ibrahim
Salah, Hager
Said, Amira S. A.
Shaaban, Ahmed Hassan
Abdou, Lamya Mohamed
Khalil, Doaa Mahmoud
Kharaba, Zelal
Afifi, Hala
Sofy, Mahmoud R.
Youssef, Eman M. I.
Bayoumy, Eman S. M.
Hussein, Raghda R. S.
author_facet Rabie, Al Shaimaa Ibrahim
Salah, Hager
Said, Amira S. A.
Shaaban, Ahmed Hassan
Abdou, Lamya Mohamed
Khalil, Doaa Mahmoud
Kharaba, Zelal
Afifi, Hala
Sofy, Mahmoud R.
Youssef, Eman M. I.
Bayoumy, Eman S. M.
Hussein, Raghda R. S.
author_sort Rabie, Al Shaimaa Ibrahim
collection PubMed
description There seem to currently be no therapeutic medications found for the severe coronavirus infection in 2019 (COVID-19). In light of this, it has been hypothesized that the immunomodulatory treatment known as tocilizumab can lessen the inflammatory response that occurs in the respiratory system, speed up the process of clinical benefit, lower the risk of death, and avert the need for ventilators. This randomized controlled trial (RCT) studied patients with a proven infection of SARS-CoV-2 and hyperinflammatory reactions. The inclusion criteria included fever (body temperature > 38 °C), pulmonary infiltrates, or supplemental oxygen. The patients received either conventional treatment with one dose of either tocilizumab (8 mg per kilogram of body weight) or conventional treatment only. The subjects were randomized to receive either treatment with a 1:1 ratio. A time-to-event test was conducted to determine the time to intubation or death. There was an insignificant difference between the investigated groups regarding the time to death, time to mechanical ventilation, and percentage of deaths. The conventional group’s median (IQR) hospital length of stay was 4 (3–6) days, whereas the tocilizumab therapy group was 7 (4.75–10) days. There was a substantial difference in the mechanical ventilation rates in both groups, which were 17 (34%) and 28 (56%), respectively. In hospitalized patients with severe illness and COVID-19, tocilizumab was ineffective in preventing intubation or death. Trials must be larger, however, in order to exclude the potential benefits or harms.
format Online
Article
Text
id pubmed-9957040
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99570402023-02-25 Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection Rabie, Al Shaimaa Ibrahim Salah, Hager Said, Amira S. A. Shaaban, Ahmed Hassan Abdou, Lamya Mohamed Khalil, Doaa Mahmoud Kharaba, Zelal Afifi, Hala Sofy, Mahmoud R. Youssef, Eman M. I. Bayoumy, Eman S. M. Hussein, Raghda R. S. Healthcare (Basel) Article There seem to currently be no therapeutic medications found for the severe coronavirus infection in 2019 (COVID-19). In light of this, it has been hypothesized that the immunomodulatory treatment known as tocilizumab can lessen the inflammatory response that occurs in the respiratory system, speed up the process of clinical benefit, lower the risk of death, and avert the need for ventilators. This randomized controlled trial (RCT) studied patients with a proven infection of SARS-CoV-2 and hyperinflammatory reactions. The inclusion criteria included fever (body temperature > 38 °C), pulmonary infiltrates, or supplemental oxygen. The patients received either conventional treatment with one dose of either tocilizumab (8 mg per kilogram of body weight) or conventional treatment only. The subjects were randomized to receive either treatment with a 1:1 ratio. A time-to-event test was conducted to determine the time to intubation or death. There was an insignificant difference between the investigated groups regarding the time to death, time to mechanical ventilation, and percentage of deaths. The conventional group’s median (IQR) hospital length of stay was 4 (3–6) days, whereas the tocilizumab therapy group was 7 (4.75–10) days. There was a substantial difference in the mechanical ventilation rates in both groups, which were 17 (34%) and 28 (56%), respectively. In hospitalized patients with severe illness and COVID-19, tocilizumab was ineffective in preventing intubation or death. Trials must be larger, however, in order to exclude the potential benefits or harms. MDPI 2023-02-17 /pmc/articles/PMC9957040/ /pubmed/36833140 http://dx.doi.org/10.3390/healthcare11040607 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rabie, Al Shaimaa Ibrahim
Salah, Hager
Said, Amira S. A.
Shaaban, Ahmed Hassan
Abdou, Lamya Mohamed
Khalil, Doaa Mahmoud
Kharaba, Zelal
Afifi, Hala
Sofy, Mahmoud R.
Youssef, Eman M. I.
Bayoumy, Eman S. M.
Hussein, Raghda R. S.
Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection
title Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection
title_full Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection
title_fullStr Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection
title_full_unstemmed Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection
title_short Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection
title_sort clinical consequences for individuals treated with tocilizumab for serious covid-19 infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957040/
https://www.ncbi.nlm.nih.gov/pubmed/36833140
http://dx.doi.org/10.3390/healthcare11040607
work_keys_str_mv AT rabiealshaimaaibrahim clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection
AT salahhager clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection
AT saidamirasa clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection
AT shaabanahmedhassan clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection
AT abdoulamyamohamed clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection
AT khalildoaamahmoud clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection
AT kharabazelal clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection
AT afifihala clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection
AT sofymahmoudr clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection
AT youssefemanmi clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection
AT bayoumyemansm clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection
AT husseinraghdars clinicalconsequencesforindividualstreatedwithtocilizumabforseriouscovid19infection